翰森制药HS-20093小细胞肺癌上市申请获NMPA受理

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility
for the contents of this announcement, make no representation as to its accuracy or completeness and expressly
disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the
contents of this announcement.

Hansoh Pharmaceutical Group Company Limited
翰森製藥集團有限公司
(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3692)

VOLUNTARY ANNOUNCEMENT
BIOLOGICS LICENSE APPLICATION OF HS-20093 FOR INJECTION FOR
SMALL CELL LUNG CANCER ACCEPTED BY THE NMPA
The board of directors (the “Board”) of Hansoh Pharmaceutical Group Company Limited (the
“Company” and together with its subsidiaries, the “Group”) is pleased to announce that, on
September 2, 2026, the biologics license application of the Group’s innovative medicine HS-20093
for injection has been accepted by the National Medical Products Administration (the “NMPA”)
of China, for the treatment of adult patients with small cell lung cancer (SCLC) after the failure
of prior platinum-based chemotherapy. HS-20093 for injection is the Group’s proprietary B7-H3
directed antibody-drug conjugate (ADC).
By Order of the Board
Hansoh Pharmaceutical Group Company Limited
Zhong Huijuan
Chairlady
Hong Kong, September 2, 2026

As at the date of this announcement, the Board comprises Ms. Zhong Huijuan as chairlady
and executive director, Ms. Sun Yuan and Dr. Lyu Aifeng as executive directors, and Mr. Lin
Guoqiang, Mr. Chan Charles Sheung Wai, Ms. Yang Dongtao and Mr. Yan Jia as independent
non-executive directors.

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性
或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚
賴該等內容而引致的任何損失承擔任何責任。

Hansoh Pharmaceutical Group Company Limited
翰森製藥集團有限公司
（於開曼群島註冊成立的有限公司）

（股份代號：3692）

自願公告
注射用HS-20093治療小細胞肺癌
上市許可申請獲國家藥品監督管理局受理
翰森製藥集團有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事會（「董
事會」）欣然宣佈，於二零二六年九月二日，本集團創新藥注射用HS-20093上市許
可申請獲中國國家藥品監督管理局(NMPA)受理，用於治療既往含鉑治療失敗的
小細胞肺癌(SCLC)成人患者。注射用HS-20093是一款本集團自主研發的B7-H3靶
向抗體 － 藥物偶聯物(ADC)。
承董事會命
翰森製藥集團有限公司
主席
鍾慧娟
香港，二零二六年九月二日

於本公告日期，董事會成員包括主席兼執行董事鍾慧娟女士、執行董事孫遠女士
及呂愛鋒博士；以及獨立非執行董事林國強先生、陳尚偉先生、楊東濤女士及嚴
嘉先生。